Monitor the tender offer conditions and regulatory approvals for the Viatris acquisition. The absence of Q3 earnings removes a near-term catalyst, and the stock will trade primarily on deal completion probability and timeline.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $36.43entry
- T+1 · 8d ago +0.08%α −2.28% · $36.46
- T+5 · 4d ago +0.08%α −2.51% · $36.46
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences will not issue its Q3 2026 earnings release or hold a conference call due to the pending acquisition by Viatris at $36.50 per share. The company has also withdrawn its 2026 financial guidance and will not provide updates during the pendency of the tender offer and merger.
Key Facts
- On October 8, 2026, Pacira entered into a merger agreement with Viatris Inc.
- On October 30, 2026, Viatris commenced a tender offer to purchase all Pacira shares for $36.50 per share in cash.
- Pacira will not issue an earnings release for the quarter ended September 30, 2026.
- Pacira is withdrawing its previously issued 2026 financial guidance.
- The merger will be effected under Section 251(h) of the DGCL following consummation of the tender offer.
Financial Impact
No financial results disclosed; acquisition consideration is $36.50 per share in cash.
Risk Factors
- The tender offer is subject to conditions including a minimum condition and regulatory approvals.
- A competing offer could emerge, though none is mentioned.
- If the deal fails, the lack of recent financial guidance and earnings creates uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071129 |
| Document: 0001628280-26-071129-index-headers.html | 0001628280-26-071129 |
| Document: 0001628280-26-071129-index.html | 0001628280-26-071129 |
| Document: 0001628280-26-071129.txt | 0001628280-26-071129 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers